Volv Global returns to Frontiers Health in Berlin this October. CEO Christopher Rudolf joins an expert panel at Frontiers Health 2026, bringing a data-grounded perspective on how AI and biomarker science can translate complex biological signals into clinical decisions that reach patients earlier.
The session
Christopher will take part in the session “From Multiomics to Clinical Intelligence: AI, Biomarkers and Precision Health” on 21 October 2026, from 9:30 to 10:30 AM. Moderated by Fredrik Debong – CEO & GP of 1921.vc, CCO of OneTwenty.ai and CCO of Syntactiq.ai – the session brings together practitioners from across AI-driven diagnostics, genomics, and precision medicine.
Advances in AI, biomarkers, and multiomic data are opening genuine pathways to earlier detection, more accurate risk assessment, and personalised health interventions. The session examines how these disciplines are converging: how biological data becomes clinical signal, how AI supports disease prediction and patient identification, and what it takes to make precision medicine actionable across diverse healthcare systems.
The format will include short introductory perspectives from each speaker, followed by a panel discussion. The other confirmed panellists are Vaibhava Lakshmi Ravideshik, AI and Growth Lead at GRAIL, and Fernando Leon, CEO of Kasvu Labs.
What Christopher will bring to the discussion
Christopher Rudolf has spent two decades at the intersection of machine learning, clinical systems, and real-world healthcare data. At Volv Global, he leads a team that applies population-scale data science to some of the most diagnostically challenging conditions – diseases where patients wait years for a correct diagnosis, and where earlier recognition changes outcomes.
His perspective on the panel is grounded in production-deployed work with leading pharmaceutical organisations across Europe and the USA. He will draw on Volv Global case studies to illustrate how machine learning applied to real-world clinical data can surface biological patterns that conventional diagnostic pathways miss – and how that intelligence can be made actionable within existing care structures, as a complement to clinical judgement.
Christopher will also address the practical conditions that determine whether precision health fulfils its promise: data quality and accessibility, governance frameworks that allow sensitive health data to be used responsibly, models validated across diverse patient populations, and the collaborative relationships between pharma, clinicians, and data partners that make translation from insight to impact possible.
About Frontiers Health 2026
Now in its eleventh year, Frontiers Health is one of Europe’s leading conferences for digital health innovation, bringing together pharmaceutical and biotech leaders, health technology companies, investors, clinicians, and policymakers. The 2026 edition focuses on AI and advanced technologies, value creation, patient- and HCP-driven innovation, and health equity – themes that sit at the heart of Volv Global’s work.
Volv Global’s participation reflects its continued engagement with the ecosystem of partners and collaborators shaping how AI is embedded into clinical and commercial healthcare practice. It is a setting where the scientific, commercial, and policy dimensions of AI in health converge – and where conversations that begin on stage often continue as partnerships that matter for patients.
Event details
- Frontiers Health 2026
- 20 – 21 October 2026
- Berlin, Germany
- From Multiomics to Clinical Intelligence: AI, Biomarkers and Precision Health
- 21 October 2026 | 9:30 – 10:30 AM
- Moderator: Fredrik Debong, CEO & GP of 1921.vc | CCO of OneTwenty.ai | CCO of Syntactiq.ai
- Panelists: Christopher Rudolf, CEO, Volv Global | Vaibhava Lakshmi Ravideshik, AI & Growth Lead, GRAIL | Fernando Leon, CEO, Kasvu Labs
Key Takeaways
- Christopher Rudolf, CEO of Volv Global, will join a panel at Frontiers Health 2026 in Berlin on 21 October 2026.
- The session examines how AI and biomarker science are converging to enable earlier diagnosis, smarter interventions, and more personalised care.
- Volv Global brings a perspective grounded in production-deployed AI applied to rare and difficult-to-diagnose diseases across real-world clinical environments.
- Fellow panellists include representatives from GRAIL and Kasvu Labs; the session is moderated by Fredrik Debong.
- For pharma leaders in clinical development, HEOR, medical affairs, and commercial excellence, the session offers a practical lens on what evidence-based AI can deliver today.
Meet us in Berlin
If you are attending Frontiers Health 2026 and would like to meet with the Volv Global team, we would be glad to hear from you. Reach out through our Contact page to book time ahead of the event.
Links
Frequently Asked Questions
What is the session topic?
“From Multiomics to Clinical Intelligence: AI, Biomarkers and Precision Health” explores how AI and multiomic data are translating complex biological signals into actionable clinical decisions – spanning disease prediction, patient identification, and personalised intervention.
What will Christopher Rudolf discuss?
Drawing on Volv Global case studies, Christopher will speak to how machine learning applied to population-scale real-world data surfaces diagnostic patterns that conventional approaches miss, and how that intelligence can be made actionable within existing care pathways.
Why does this matter for pharmaceutical organisations?
For teams across clinical development, HEOR, medical affairs, and commercial excellence, precision health intelligence shapes decisions from trial enrolment and patient stratification through to launch sequencing and real-world evidence generation. The session offers a grounded view of where validated AI is already delivering results.
How can I meet Volv Global at Frontiers Health 2026?
If you would like to arrange a meeting in Berlin, please contact us through the Contact page on our website. We look forward to the conversation.
